Sangamo BioSciences, Inc. (Nasdaq: SGMO) today said they expect top-line efficacy data of their Phase 2b Clinical Trial in Diabetic Neuropathy in 2H 2011. Previous guidance released in February was for data during 4Q 2011.
Columbia Laboratories, Inc. (Nasdaq: CBRX), and Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced that they had submitted their NDA for PROCHIEVE (progesterone gel) for the reduction of risk of preterm birth in women with short uterine cervical length in the mid-trimester of pregnancy. A 6-month priority review was requested. If a priority review is accepted, an end-of-September PDUFA date is expected. A standard 10-month review would result in a likely PDUFA date during late February 2012.